User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Clinical practice treatment of HIV infection in children

Primary tabs

Brichard, Bénédicte [UCL] Van der Linden, Dimitri [UCL]

Perinatal transmission remains the main cause of HIV infection in the pediatric population. Treatment of HIV-infected children has become less of a problem in resource-rich countries with a remarkable decrease of perinatal infections, resulting in an effective prevention of mother-to-child transmission and antiretroviral treatment of HIV infection in pediatrics because of differences in drug pharmacokinetics, the lack of available licensed drugs, the use of different immunologic markers and age-related adherence issues. This review, for the general pediatrician, summarizes the most recent pediatric data and guidelines for treatment of HIV. Recommendations for when to initiate therapy are more aggressive in children than in adults, particularly in infants because disease progression in children is more rapid. The indications to start therapy differ by age and are based on international immunologic and clinical classification system for HIV infection. At present, combination regimens of at least three drugs are recommended. Moreover, therapies must also consider the potential complications in these children currently treated for a long time.

Document type Article de périodique (Journal article) – Synthèse de littérature – Journal Article, Review
Access type Accès restreint
Publication date 2009
Language Anglais
Journal information "European Journal of Pediatrics" - Vol. 168, no. 4, p. 387-392 (2009)
Peer reviewed yes
Publisher Springer ((Germany) Heidelberg)
issn 0340-6199
e-issn 1432-1076
Publication status Publié
Affiliations UCL - MD/GYPE - Département de gynécologie, d'obstétrique et de pédiatrie
UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique
UCL - (SLuc) Service de pédiatrie spécialisée
MESH Subject Treatment Outcome ; Severity of Illness Index ; Reverse Transcriptase Inhibitors - therapeutic use ; Protease Inhibitors - therapeutic use ; Practice Guidelines as Topic ; Physician's Practice Patterns ; Pediatrics - methods ; Integrase Inhibitors - therapeutic use ; Infant, Newborn ; Infant ; Humans ; HIV Infections - diagnosis - drug therapy ; HIV Fusion Inhibitors - therapeutic use ; Drug Therapy, Combination ; Drug Resistance, Viral ; Clinical Protocols ; Child, Preschool ; Child ; Anti-Retroviral Agents - therapeutic use ; Age Factors
Links
  1. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ (1999) Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 25:316–319
  2. Blanche Stéphane, Newell Marie-Louise, Mayaux Marie-Jeanne, Dunn David T., Teglas Jean Paul, Rouzioux Christine, Peckham Catherine S., Morbidity and Mortality in European Children Vertically Infected by HIV-1 : The French Pediatric HIV Infection Study Group and European Collaborative Study, 10.1097/00042560-199704150-00008
  3. Centers for Disease Control and Prevention (CDC) (2007) Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings. MMWR Recomm Rep 55:1–17
  4. Centers for Disease Control and Prevention (1994) 994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 43:1–10
  5. Centers for Disease Control and Prevention (2001) Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 50:63–85
  6. Chakraborty R (2005) HIV-1 infection in children: a clinical and immunologic overview. Curr HIV Res 3:31–41
  7. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee (2008) Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 22:97–105
  8. Dao H, Mofenson LM, Ekpini R et al (2007) International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol 197:S42–S55
  9. Day E, Buckberry K, Sharland MR, Chakraborty R (2008) Novel treatment options for pediatric HIV infection. Curr Opin Investig Drugs 9:170–175
  10. Durant J, Clevenbergh P, Halfon P et al (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195–2199
  11. Eley B (2008) Metabolic complications of antiretroviral therapy in HIV-infected children. Expert Opin Drug Metab Toxicol 4:37–49
  12. Eley B, Nuttall J (2007) Antiretroviral therapy for children: challenges and opportunities. Ann Trop Paediatr 27:1–10
  13. European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18:1443–1451
  14. Goetghebuer T, Haelterman E, Le Chenadec J et al (2008) Early vs deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study. Retrovirology 5(suppl 1):O25
  15. Giaquinto C, Rampon O, Penazzato M et al (2007) Nucleoside and nucleotide reverse transcriptase inhibitors in children. Clin Drug Investig 27:509–531
  16. Gray L, Newell ML, Thorne C et al (2001) Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 108:116–122
  17. Green H, Gibb DM, Walker AS, Paediatric European Network for the Treatment of AIDS (PENTA) et al (2007) Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 21:947–955
  18. HIV Paediatric Prognostic Markers Collaborative Study (2005) Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 366:1868–1874
  19. Ikeda T, Ch’ng TW, Oleske JM (2007) Recommendations in pediatric antiretroviral therapy. Expert Opin Pharmacother 8:155–166
  20. Lujan-Zilbermann J, Rodriguez CA, Emmanuel PJ (2006) Pediatric HIV infection: diagnostic laboratory methods. Fetal Pediatr Pathol 25:249–260
  21. Luzuriaga K, McManus M, Mofenson L, PACTG 356 Investigators et al (2004) A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med 350:2471–2480
  22. McKellar MS, Callens SF, Colebunders R (2008) Pediatric HIV infection: the state of antiretroviral therapy. Expert Rev Anti Infect Ther 6:167–180
  23. Prendergast A, Tudor-Williams G, Jeena P et al (2007) International perspectives, progress and future challenges of paediatric HIV infection. Lancet 370:68–80
  24. Resino S, Resino R, Micheloud D, Spanish Group of Paediatric HIV infection et al (2006) Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 42:862–869
  25. Starr SE, Fletcher CV, Spector SA, PACTG 382 Study Team. Pediatric AIDS Clinical Trials Group et al (2002) Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21:659–663
  26. Van der Linden D, Hainaut M, Goetghebuer T et al (2007) Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J 26:359–361
  27. Violari A, Cotton MF, Gibb DM et al (2008) Early antiretroviral therapy and mortality among HIV-infected infants. The CHER Study Team N Engl J Med 359:2233–2244
  28. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected children (2008) Guidelines for the use of antiretroviral gents in pediatric HIV infection and pediatric antiretroviral drug information. http://AIDSinfo.nih.gov
  29. WHO (2008) Paediatric HIV and treatment of children living with HIV. www.who.int/hiv/paediatric/en/index.html
Bibliographic reference Brichard, Bénédicte ; Van der Linden, Dimitri. Clinical practice treatment of HIV infection in children. In: European Journal of Pediatrics, Vol. 168, no. 4, p. 387-392 (2009)
Permanent URL http://hdl.handle.net/2078.1/20974